DK0690726T3 - Antisense-inhibibering af c-myc til modulering af proliferationen af glat muskel-celler - Google Patents

Antisense-inhibibering af c-myc til modulering af proliferationen af glat muskel-celler

Info

Publication number
DK0690726T3
DK0690726T3 DK94906558T DK94906558T DK0690726T3 DK 0690726 T3 DK0690726 T3 DK 0690726T3 DK 94906558 T DK94906558 T DK 94906558T DK 94906558 T DK94906558 T DK 94906558T DK 0690726 T3 DK0690726 T3 DK 0690726T3
Authority
DK
Denmark
Prior art keywords
cell proliferation
smooth muscle
muscle cell
myc
pct
Prior art date
Application number
DK94906558T
Other languages
English (en)
Inventor
Andrew Zalewski
Yi Shi
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Application granted granted Critical
Publication of DK0690726T3 publication Critical patent/DK0690726T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK94906558T 1993-01-07 1994-01-07 Antisense-inhibibering af c-myc til modulering af proliferationen af glat muskel-celler DK0690726T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US479993A 1993-01-07 1993-01-07
PCT/US1994/000265 WO1994015646A1 (en) 1993-01-07 1994-01-07 Antisense inhibition of c-myc to modulate the proliferation of smooth muscle cells

Publications (1)

Publication Number Publication Date
DK0690726T3 true DK0690726T3 (da) 2002-03-11

Family

ID=21712588

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94906558T DK0690726T3 (da) 1993-01-07 1994-01-07 Antisense-inhibibering af c-myc til modulering af proliferationen af glat muskel-celler

Country Status (16)

Country Link
US (1) US6159946A (da)
EP (1) EP0690726B1 (da)
JP (1) JPH08505397A (da)
KR (1) KR100316205B1 (da)
CN (1) CN1119830A (da)
AT (1) ATE208634T1 (da)
AU (1) AU685080B2 (da)
BR (1) BR9405707A (da)
CA (1) CA2153158A1 (da)
CZ (1) CZ172395A3 (da)
DE (1) DE69429087T2 (da)
DK (1) DK0690726T3 (da)
ES (1) ES2167358T3 (da)
HU (1) HU220969B1 (da)
PT (1) PT690726E (da)
WO (1) WO1994015646A1 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ES2167358T3 (es) * 1993-01-07 2002-05-16 Univ Jefferson Inhibicion antisentido de c-myc para modular la proliferacion de celulas de musculo liso.
US6323184B1 (en) 1993-10-15 2001-11-27 Thomas Jefferson University Arteriovenous and venous graft treatments: methods and compositions
US6133242A (en) * 1993-10-15 2000-10-17 Thomas Jefferson Univerisity Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes
DE69429539T2 (de) * 1993-10-15 2002-09-05 Thomas Jefferson University, Philadelphia Inhibierung der synthese von extrazellulärer matrix mittels "antisense"-zusammensetzungen, die gegen c-myc gerichtet sind
AU4923696A (en) * 1995-02-10 1996-08-27 Nexstar Pharmaceuticals, Inc. Lipid constructs for cytoplasmic delivery of agents
US5660855A (en) * 1995-02-10 1997-08-26 California Institute Of Technology Lipid constructs for targeting to vascular smooth muscle tissue
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
WO1997014440A1 (en) * 1995-10-19 1997-04-24 Johnson & Johnson Interventional Systems Conjugation of c-myc antisense oligonucleotides with cholesterol to significantly enhance their inhibitory effect on neointimal hyperplasia
US5681558A (en) * 1995-11-30 1997-10-28 Berlex Laboratories, Inc. Method of using beta-interferons to treat restenosis
CA2286304C (en) 1997-04-10 2007-08-07 Diagnocure Inc. Pca3, pca3 genes, and methods of use
WO2000009672A1 (en) * 1998-08-13 2000-02-24 Johnson & Johnson Research Pty. Limited Dnazymes and methods for treating restenosis
US7094765B1 (en) * 1999-01-29 2006-08-22 Avi Biopharma, Inc. Antisense restenosis composition and method
WO2000045167A2 (en) * 1999-01-29 2000-08-03 Avi Biopharma, Inc. Non-invasive method for detecting target rna
KR20000065690A (ko) * 1999-04-08 2000-11-15 박종구 반응 특이성 및 안정성을 개선시킨 안티센스 올리고 뉴클레오타이드, 안티센스 ｄｎａ 및 그 제조방법
US7368545B1 (en) 1999-09-29 2008-05-06 Diagnocure Inc. PCA3 messenger RNA species in benign and malignant prostate tissues
WO2001052915A1 (en) * 2000-01-24 2001-07-26 Biocompatibles Limited Coated implants
AU2001255179A1 (en) * 2000-03-24 2001-10-08 Temple University-Of The Commonwealth System Of Higher Education Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targeting agents
AU2002224787A1 (en) * 2000-10-23 2002-05-06 Mermaid Pharmaceuticals Gmbh Method for temporally controlling antisense-mediated gene inactivation
CA2447052A1 (en) * 2001-05-17 2002-11-21 Avi Biopharma, Inc. Combined approach to treatment of cancer using a c-myc antisense oligomer
US20050159378A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US7893248B2 (en) * 2002-02-20 2011-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US7241581B2 (en) * 2002-08-16 2007-07-10 Rigel Pharmaceuticals, Inc. Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a c-MYC protein
US7407672B2 (en) * 2002-11-04 2008-08-05 National Heart Center Composition derived from biological materials and method of use and preparation
AU2003294281B2 (en) 2002-11-13 2010-05-20 Kastle Therapeutics, Llc Antisense modulation of apolipoprotein B expression
SI2336318T1 (sl) 2002-11-13 2013-07-31 Genzyme Corporation Protismiselna modulacija ekspresije apolipoproteina B
US7781415B2 (en) * 2003-02-07 2010-08-24 Roche Madison Inc. Process for delivering sirna to cardiac muscle tissue
CA2513780C (en) 2003-02-07 2014-12-30 Diagnocure Inc. Method to detect prostate cancer from a urine sample
DE602004028930D1 (de) * 2003-04-29 2010-10-14 Avi Biopharma Inc Zusammensetzungen zur verbesserung der antisense-wirksamkeit und des transports von nukleinsäureanalog in zellen
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
KR100818047B1 (ko) 2005-11-25 2008-03-31 한국원자력연구원 평활근-22α의 활성을 억제하여 암세포의 사멸을 촉진하는방법 및 평활근-22α의 활성 억제제를 유효성분으로포함하는 항암제
WO2009005793A2 (en) * 2007-06-29 2009-01-08 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
JP6091752B2 (ja) * 2008-12-04 2017-03-08 クルナ・インコーポレーテッド Ｅｐｏに対する天然アンチセンス転写物の抑制によるエリスロポエチン（ｅｐｏ）関連疾患の治療
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
US8946182B2 (en) * 2010-01-25 2015-02-03 Curna, Inc. Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
JP6049623B2 (ja) * 2010-10-22 2016-12-21 カッパーアールエヌエー，インコーポレイテッド α‐Ｌ‐イズロニダーゼ（ＩＤＵＡ）への天然アンチセンス転写物の阻害によるＩＤＵＡ関連疾患の治療
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
US9228189B2 (en) * 2012-10-26 2016-01-05 Geron Corporation C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
PT3554553T (pt) 2016-12-19 2022-08-04 Sarepta Therapeutics Inc Conjugados oligoméricos de salto de exão para a distrofia muscular

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264423A (en) * 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
SE462364B (sv) * 1988-09-30 1990-06-18 Goeran Hansson Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos
JPH06502300A (ja) * 1990-08-03 1994-03-17 サノフィ 遺伝子発現の抑制のための化合物及び方法
US5245022A (en) * 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5122048A (en) * 1990-09-24 1992-06-16 Exxon Chemical Patents Inc. Charging apparatus for meltblown webs
EP0558697A1 (en) * 1991-06-28 1993-09-08 Massachusetts Institute Of Technology Localized oligonucleotide therapy
WO1993008845A1 (en) * 1991-11-08 1993-05-13 Massachusetts Institute Of Technology Localized oligonucleotide therapy
US5756476A (en) * 1992-01-14 1998-05-26 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of cell proliferation using antisense oligonucleotides
US5821234A (en) * 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
AU5961094A (en) * 1992-12-31 1994-08-15 Texas Biotechnology Corporation Antisense molecules directed against a platelet derived growth factor receptor related gene
WO1994015645A1 (en) * 1992-12-31 1994-07-21 Texas Biotechnology Corporation Antisense molecules directed against genes of the raf oncogene family
ES2167358T3 (es) * 1993-01-07 2002-05-16 Univ Jefferson Inhibicion antisentido de c-myc para modular la proliferacion de celulas de musculo liso.
DE69432413T2 (de) * 1993-06-11 2004-05-13 The Board Of Trustees Of The Leland Stanford Junior University, Stanford Behandlung degenerativer gefaesserkrankungen durch modulation der endogenen stickoxidproduktion oder-aktivitaet
DE69429539T2 (de) * 1993-10-15 2002-09-05 Thomas Jefferson University, Philadelphia Inhibierung der synthese von extrazellulärer matrix mittels "antisense"-zusammensetzungen, die gegen c-myc gerichtet sind

Also Published As

Publication number Publication date
EP0690726B1 (en) 2001-11-14
ES2167358T3 (es) 2002-05-16
EP0690726A4 (en) 1998-10-07
EP0690726A1 (en) 1996-01-10
DE69429087D1 (de) 2001-12-20
US6159946A (en) 2000-12-12
DE69429087T2 (de) 2002-07-11
PT690726E (pt) 2002-05-31
KR100316205B1 (ko) 2002-04-24
AU685080B2 (en) 1998-01-15
CA2153158A1 (en) 1994-07-21
HU220969B1 (hu) 2002-07-29
JPH08505397A (ja) 1996-06-11
AU6023594A (en) 1994-08-15
BR9405707A (pt) 1996-08-06
KR960700076A (ko) 1996-01-19
WO1994015646A1 (en) 1994-07-21
HUT71937A (en) 1996-02-28
HU9502061D0 (en) 1995-09-28
CN1119830A (zh) 1996-04-03
ATE208634T1 (de) 2001-11-15
CZ172395A3 (en) 1996-03-13

Similar Documents

Publication Publication Date Title
DK0690726T3 (da) Antisense-inhibibering af c-myc til modulering af proliferationen af glat muskel-celler
MX9606401A (es) Compuesto de indolinona para el tratamiento de enfermedades.
ZA987491B (en) Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
UA85036C2 (ru) Ингибитор и стимулятор пролиферации стволовых клеток и их использование
MX9801093A (es) Inhibidores de la proteinasa c para el tratamiento de enfermedades relacionadas con la sobreproduccion de colagena.
IL109177A0 (en) Inhibitor of stem cell proliferation and uses thereof
DE69633566D1 (de) Orotatsalze von 5-amino- oder substituierten amino-1,2,3-triazolen zur behandlung von neoplasmen
ATE321452T1 (de) Tetracycline verbindungen zur behandlung von spezifischen krebsarten
CY2473B1 (en) New phenanthridines.
ATE331521T1 (de) Behandlung von schmerzen
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
IL136767A0 (en) Inhibition of raf kinase using substituted heterocyclic ureas
PL341356A1 (en) Raf kinase inhibition employing aryl- and heteroaryl-substituted heterocyclic ureas
DK0907631T3 (da) Uorganiske ionreceptoraktive forbindelser
DE69532813D1 (de) Inhibitor der stammzellenproliferation und dessen verwendung
EP0646007A4 (da)
DK1019490T3 (da) Fremgangsmåder til modulering af hæmatopoese og vaskulær vækst
DE69825286D1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
MX9702035A (es) Inhibidores de 5-alfa reductasa.
DE69510545D1 (de) Cck oder gastrin modulierende 5-heterocyclicyl-1,5-benzodiazepine
AU5818394A (en) Use of prodelphinidines for treating arthrosis
ATE309352T1 (de) Inhibitoren der nf-kb aktivierung
GB9310400D0 (en) Curable compositions
GB9607119D0 (en) Compounds
AR010987A1 (es) Composicion farmaceutica y metodo para tratar un trastorno compulsivo.